Food Allergy Research & Education (FARE) continues innovation through accelerated therapy, diagnostics and prevention strategies
Now Enrolling: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH)
Study Objectives & Details: Our researchers are trying to determine if a study medication called omalizumab alone or combined with oral immunotherapy may help people with multiple food allergies. Participants must have a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut, or walnut.
Enrollment: This trial is active and currently enrolling.
How to Participate: For more information, call (404) 785-6448 to speak with a coordinator or email email@example.com
Who Can Participate: Anyone between the ages of 2-55 years who has a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut or walnut.
Age Range: 2-55 years
Estimated Time Commitment (# of visits, etc.): This is a multi-stage study, with an individual study participation of up to 4 years and 8 months, but not past December 2023.
Study Location: Children’s Healthcare of Atlanta - Center for Advanced Pediatrics
Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Site Principal Investigator: Brian Vickery, MD
Study Coordinators: Ashley Dulson and Mary Vess
Study Primary Investigator: Robert Wood, MD
Co-Investigator(s): Jennifer Shih, MD and Meera Patrawala, MD
- OUtMATCH: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants - Open to ages 2-55
- EPITOPE: Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
- Poseidon: Peanut Oral Immunotherapy Study of Early Intervention for Desensitization - Open to ages 1-3
If you or your child are interested in enrolling in one of these studies, please send an e-mail to firstname.lastname@example.org and let us know which study or studies you are interested in and we will send more information!
No longer enrolling:
- Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) - for ages 6-17
Thank you for your interest! Clinical research connects patients and families with experimental treatments and provides critically needed data to advance the field. The treatments of tomorrow are not possible without it.
If you are interested in learning more about experimental treatments for food allergy and potentially participating in a study, please click here to register yourself and/or your child. One of our team will be in touch afterwards if you qualify for a study.
Have a question? E-mail us: email@example.com
To hear more about participating in a clinical trial, you're invited to watch this recording of a recent community event which covered a variety of topics including clinical trials at Children's, Food Allergy Clinical Trials, and what participation in a trial is like for families.
Millions of children worldwide suffer from food allergies, a poorly understood group of immune-mediated conditions that leave these children susceptible to serious allergic reactions and the psychosocial burdens of living with a chronic, unpredictable, and life-threatening disorder.
The mission of the Food Allergy Center at Emory + Children’s is to perform impactful research and deliver high-quality, high-value, patient-centered care to transform the lives of those affected by food allergy in the Southeast and beyond. The four core domains of this mission are:
To provide state-of-the-art clinical care to patients with food allergies and related conditions;
To create and disseminate new knowledge through research;
To advocate for children through stakeholder engagement at all levels; and
To provide a world-class training experience for the next generation of clinicians and scholars.
Our Philosophy and Vision
We will become a national leader in the study and treatment of food allergy and related conditions while adhering to the following five foundational principles:
- We are patient-centered: Everything we do is focused on meeting patient needs.
- We act with integrity: We hold ourselves to the highest moral and ethical standards.
- We treat all persons with dignity and respect: Everyone. All the time. No exceptions.
- We do not quit: 99% of success in science is not giving up. Our patients depend on it.
- We are a team: We are supportive of, and accountable to, one another. We have fun.
- Brian P. Vickery, MD
- Lisa Kobrynski, MD
- Merin Kuruvilla, MD
- Gerald Lee, MD
- Jennifer Shih, MD
- Codi Horton, CPNP
- Brian P. Vickery, MD
- Ashley Dulson, CCRP
- Kristin Roberts, MSHM
- Mary Vess, MSN, RN
- Ankit Mathur, MD
- Meera Patrawala, MD
To view a list of Dr. Vickery's publications on PubMed, please click this link.
This video is several years old now but still articulates beautifully why clinical research is critical to move this field forward.
Consortium of Food Allergy Research (in particular the "Food Allergy Education Program" tab)
Food Allergy Resources from the National Institutes of Allergy and Infectious Disease
Food Allergy Research and Resource Program from the University of Nebraska, Lincoln
FDA - Food Allergies: What You Need to Know
CDC - Food Allergies in Schools and other resources
Dr. Brian Vickery is a pediatric allergist-immunologist whose clinical and research efforts focus on understanding the pathophysiology of food allergies and anaphylaxis, and developing new therapies to treat them. He has studied all aspects of therapeutic development, from preclinical murine models to Phase 3 trials, and is particularly focused on the intersection of translational and outcomes research in generating rational, evidence-driven treatment strategies. He is currently an Associate Professor of Pediatrics at Emory University and the founding Director of the Food Allergy Center at Children’s Healthcare of Atlanta.
Dr. Vickery completed his undergraduate work at the University of Georgia and then obtained his medical degree from the Medical College of Georgia. He completed his pediatric residency and chief residency at New York-Presbyterian Hospital/Weill Cornell Medical Center, and his fellowship training in allergy & clinical immunology at Yale University School of Medicine, where he worked on a preclinical model of the investigational peanut allergy vaccine EMP-123 in the laboratory of Kim Bottomly, PhD. He subsequently held faculty positions at Duke University School of Medicine and then the University of North Carolina School of Medicine, where he was an NIH-funded researcher and the Director of the UNC Food Allergy Initiative. At UNC, he led a group that was first to show that sustained unresponsiveness (SU), or clinical remission, can occur after peanut oral immunotherapy (OIT) and subsequently demonstrated for the first time that the early treatment of peanut-allergic preschool children with OIT is safe and enhances the likelihood of SU. Prior to joining the Emory faculty, he led an international Phase 3 randomized clinical trial of peanut OIT, the largest of its kind, as senior medical director at Aimmune Therapeutics.
Dr. Vickery has published over 50 papers in leading journals, and serves as a peer reviewer for high-impact allergy journals and grant agencies, as well as a journal section editor. He has presented his work at national and international meetings and has contributed to the development of national food allergy treatment guidelines. He has received several awards for clinical care as well as research awards from the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American College of Allergy, Asthma, and Immunology, and the British Society of Allergy and Clinical Immunology. He is active in the AAAAI, having held leadership positions on several committees, and is a member of FARE’s Outcomes Research Advisory Board. He is committed to developing the careers of the next generation of clinicians and researchers in allergy, and over the last 10 years has mentored 12 trainees, 9 of whom are in the academic or public sector.